Gainers
- iSpecimen (NASDAQ:ISPC) shares increased by 80.7% to $1.35 during Tuesday's regular session. The company's market cap stands at $6.1 million.
- Tourmaline Bio (NASDAQ:TRML) shares increased by 57.75% to $47.61. The company's market cap stands at $775.3 million.
- Adagene (NASDAQ:ADAG) stock rose 19.73% to $2.86. The company's market cap stands at $112.5 million.
- Telomir Pharmaceuticals (NASDAQ:TELO) stock rose 16.26% to $1.43. The market value of their outstanding shares is at $39.7 million.
- Cyclerion Therapeutics (NASDAQ:CYCN) shares increased by 15.92% to $2.62. The company's market cap stands at $7.2 million.
- ProPhase Labs (NASDAQ:PRPH) stock increased by 15.12% to $0.44. The market value of their outstanding shares is at $15.7 million.
Losers
- PACS Group (NYSE:PACS) stock declined by 31.3% to $7.78 during Tuesday's regular session. The market value of their outstanding shares is at $1.7 billion.
- Silexion Therapeutics (NASDAQ:SLXN) stock declined by 29.72% to $4.99. The company's market cap stands at $5.1 million.
- Abpro Hldgs (NASDAQ:ABP) stock declined by 20.26% to $0.17. The company's market cap stands at $17.4 million.
- Galecto (NASDAQ:GLTO) stock fell 18.45% to $2.52. The company's market cap stands at $4.0 million.
- CDT Equity (NASDAQ:CDT) shares fell 18.45% to $0.65. The company's market cap stands at $2.4 million.
- Elutia (NASDAQ:ELUT) stock decreased by 18.36% to $1.53. The market value of their outstanding shares is at $79.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ADAGAdagene Inc
$1.77-%
CDTCDT Equity Inc
$2.25-9.64%
CYCNCyclerion Therapeutics Inc
$1.40-1.41%
ELUTElutia Inc
$0.74290.36%
GLTOGalecto Inc
$27.8418.0%
ISPCiSpecimen Inc
$0.6001-5.50%
PACSPACS Group Inc
$10.70-6.63%
PRPHProPhase Labs Inc
$0.2590-3.32%
SLXNSilexion Therapeutics Corp
$2.961.72%
TELOTelomir Pharmaceuticals Inc
$1.34-0.74%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
